Town & Country Bank & Trust CO dba First Bankers Trust CO Grows Holdings in Stryker Corporation $SYK

Town & Country Bank & Trust CO dba First Bankers Trust CO raised its position in Stryker Corporation (NYSE:SYK) by 13.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,063 shares of the medical technology company’s stock after buying an additional 1,850 shares during the period. Stryker accounts for 1.8% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s investment portfolio, making the stock its 14th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Stryker were worth $5,278,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new position in shares of Stryker in the fourth quarter valued at approximately $1,822,272,000. Auto Owners Insurance Co lifted its holdings in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares during the period. Wellington Management Group LLP boosted its position in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after purchasing an additional 1,198,665 shares during the last quarter. Corient Private Wealth LLC grew its stake in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the period. Finally, Alliancebernstein L.P. grew its stake in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after purchasing an additional 741,542 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last three months. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

SYK has been the topic of a number of research analyst reports. Barclays cut their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. JPMorgan Chase & Co. lowered their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. William Blair reiterated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Evercore set a $355.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Stock Up 0.3%

Shares of NYSE SYK opened at $308.62 on Monday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $118.31 billion, a P/E ratio of 35.72, a P/E/G ratio of 1.97 and a beta of 0.78. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The business has a 50-day simple moving average of $313.81 and a two-hundred day simple moving average of $341.50.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.